Every material Form 8-K Praxis Precision Medicines, Inc. has filed with the SEC since July 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Praxis Precision Medicines reported a third-quarter 2026 net loss of $94.2 million, up from $73.9 million a year earlier, while its loss per share narrowed to $3.23 from $3.36 on a larger share count. The company had $1.3 billion in cash and investments at September 30, 2026, which it says funds operations into 2028, and it has two FDA applications under review with target action dates of December 27, 2026 and January 29, 2027.
Net loss was $94.2 million for Q3 2026 versus $73.9 million for Q3 2025; loss per share was $3.23 versus $3.36.
General and administrative expenses rose to $42.7 million from $12.6 million, mainly on $17.2 million in higher personnel costs and $9.4 million in higher professional expenses.
Cash, cash equivalents and marketable securities were $1.3 billion at September 30, 2026, which the company says funds operations into 2028.
FDA target action dates are December 27, 2026 for relutrigine and January 29, 2027 for ulixacaltamide; Investor Day is November 12, 2026.
Praxis Precision Medicines reported a second-quarter 2026 net loss of $83.7 million, up from $71.1 million in the same quarter of 2025, as research and development and general and administrative expenses both rose. The company said the FDA completed mid-cycle meetings and BIMO inspections for its two pending applications, and that cash and investments of $1.4 billion fund operations into 2028.
Net loss of $83.7 million for Q2 2026 versus $71.1 million for Q2 2025; loss per share was $2.87 versus $3.31
General and administrative expenses rose to $27.5 million from $13.1 million, mainly due to $7.2 million in higher professional expenses
Relutrigine PDUFA target action date set at December 27, 2026; ulixacaltamide PDUFA date is January 29, 2027
Cash, cash equivalents and marketable securities of $1.4 billion as of June 30, 2026
Praxis Precision Medicines entered a research collaboration and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide, its essential tremor candidate. The company also made an equity investment in Remagine, and says the transdermal option could broaden the patient population and strengthen the drug's competitive position.
Agreement announced July 7, 2026, with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems
Remagine's platform is designed for precise, multi-day active transdermal dosing of ulixacaltamide for essential tremor
Praxis made an equity investment in Remagine; the filing does not disclose the amount or financial terms
The patch is intended to complement the company's lead oral program for ulixacaltamide
Praxis Precision Medicines approved the dismissal of Ernst & Young LLP as its independent registered public accounting firm and engaged KPMG LLP as its new auditor, both effective June 29, 2026. The filing states that EY's reports for fiscal 2025 and 2024 contained no adverse opinion, disclaimer, or qualification, and that no disagreements or reportable events occurred with EY.
Audit Committee approved the dismissal of EY and the engagement of KPMG on June 29, 2026.
EY's audit reports for fiscal years 2025 and 2024 had no adverse opinion, disclaimer, or qualification.
The company reports no disagreements or reportable events with EY through June 29, 2026.
EY's letter to the SEC, dated July 2, 2026, is filed as Exhibit 16.1.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Praxis Precision Medicines, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →